Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-08

AUTHORS

H. Espérou, M.-C. Jars-Guincestre, F. Bolgert, J.-C. Raphaël, I. Durand-Zaleski, and the French Cooperative Group ¶on Plasma Exchange ¶in Guillain-Barré Syndrome

ABSTRACT

Objective: To undertake a cost analysis of therapeutic strategies with plasma exchange (PE) for the treatment of patients with Guillain-Barré syndrome. Design: A randomized clinical trial including 556 patients with Guillain-Barré syndrome. We demonstrated that in the group with mild disease (walking possible) two PEs were more effective than none in shortening the time to beginning motor recovery. In the groups with moderate disease (walking impossible) and or severe disease (mechanically ventilated patients) four sessions were more effective than two and no more effective than six in shortening the time to recovery of walking with assistance and for the recovery rate of full muscle strength within 1 year. Data on outcomes and costs was collected. Complete cost data were available on 546 from the 556 patients of the trial. Costs were estimated from the viewpoint of the healthcare system and computed over a 1-year period. Because the analysis of medical outcomes did not show any difference regarding mortality but only on intermediate short-term and long-term outcomes, we carried out a cost minimization analysis. Results: In two groups a dominant strategy appeared, with greater efficacy and lower costs in the two-PE arm for the mild group: 21,353 euros vs. 38,753 euros and in the four-PE arm in the moderate group: 59,480 euros vs. 80,737 euros. In the severe group four PEs were as efficient and somewhat less expensive than six: 57,621 vs. 61,056 euros. Conclusion: The treatment of Guillain-Barré syndrome by PE at the onset of disease appears to have medical justification. The least expensive strategies are either more or equally efficient as more expensive strategies. More... »

PAGES

1094-1100

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s001340051323

DOI

http://dx.doi.org/10.1007/s001340051323

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030486404

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11030166


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guillain-Barre Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasma Exchange", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Statistics, Nonparametric", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology,  Saint Louis Hospital, Paris, France, FR", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "Department of Hematology,  Saint Louis Hospital, Paris, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Esp\u00e9rou", 
        "givenName": "H.", 
        "id": "sg:person.0706141501.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706141501.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Intensive Care Unit,  Raymond Poincar\u00e9 Hospital, Paris, France, FR", 
          "id": "http://www.grid.ac/institutes/grid.414291.b", 
          "name": [
            "Medical Intensive Care Unit,  Raymond Poincar\u00e9 Hospital, Paris, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jars-Guincestre", 
        "givenName": "M.-C.", 
        "id": "sg:person.015267023654.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015267023654.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Intensive Care Unit,  La Salp\u00e9tri\u00e8re Hospital, Paris, France, FR", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Medical Intensive Care Unit,  La Salp\u00e9tri\u00e8re Hospital, Paris, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bolgert", 
        "givenName": "F.", 
        "id": "sg:person.01006317031.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006317031.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Intensive Care Unit,  Raymond Poincar\u00e9 Hospital, Paris, France, FR", 
          "id": "http://www.grid.ac/institutes/grid.414291.b", 
          "name": [
            "Medical Intensive Care Unit,  Raymond Poincar\u00e9 Hospital, Paris, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rapha\u00ebl", 
        "givenName": "J.-C.", 
        "id": "sg:person.012632056144.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012632056144.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health,  Henri Mondor Hospital AP-HP,  Sant\u00e9 Publique, H\u00f4pital Henri Mondor,  51 avenue du Mar\u00e9chal de Lattre deTassigny, 94 010 Cr\u00e9teil, France e-mail: isabelle.durand-zaleski@hmn. ap-hop-paris.fr Tel.: + 33-1-49 81 36 74 Fax: + 33-1-49 81 36 97, FR", 
          "id": "http://www.grid.ac/institutes/grid.412116.1", 
          "name": [
            "Department of Public Health,  Henri Mondor Hospital AP-HP,  Sant\u00e9 Publique, H\u00f4pital Henri Mondor,  51 avenue du Mar\u00e9chal de Lattre deTassigny, 94 010 Cr\u00e9teil, France e-mail: isabelle.durand-zaleski@hmn. ap-hop-paris.fr Tel.: + 33-1-49 81 36 74 Fax: + 33-1-49 81 36 97, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "I.", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "and the French Cooperative Group \u00b6on Plasma Exchange \u00b6in Guillain-Barr\u00e9 Syndrome", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001340050595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048034615", 
          "https://doi.org/10.1007/s001340050595"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4899-3115-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109705857", 
          "https://doi.org/10.1007/978-1-4899-3115-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-08", 
    "datePublishedReg": "2000-08-01", 
    "description": "Objective: To undertake a cost analysis of therapeutic strategies with plasma exchange (PE) for the treatment of patients with Guillain-Barr\u00e9 syndrome. Design: A randomized clinical trial including 556 patients with Guillain-Barr\u00e9 syndrome. We demonstrated that in the group with mild disease (walking possible) two PEs were more effective than none in shortening the time to beginning motor recovery. In the groups with moderate disease (walking impossible) and or severe disease (mechanically ventilated patients) four sessions were more effective than two and no more effective than six in shortening the time to recovery of walking with assistance and for the recovery rate of full muscle strength within 1 year. Data on outcomes and costs was collected. Complete cost data were available on 546 from the 556 patients of the trial. Costs were estimated from the viewpoint of the healthcare system and computed over a 1-year period. Because the analysis of medical outcomes did not show any difference regarding mortality but only on intermediate short-term and long-term outcomes, we carried out a cost minimization analysis. Results: In two groups a dominant strategy appeared, with greater efficacy and lower costs in the two-PE arm for the mild group: 21,353 euros vs. 38,753 euros and in the four-PE arm in the moderate group: 59,480 euros vs. 80,737 euros. In the severe group four PEs were as efficient and somewhat less expensive than six: 57,621 vs. 61,056 euros. Conclusion: The treatment of Guillain-Barr\u00e9 syndrome by PE at the onset of disease appears to have medical justification. The least expensive strategies are either more or equally efficient as more expensive strategies.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s001340051323", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "keywords": [
      "Guillain-Barr\u00e9 syndrome", 
      "plasma exchange", 
      "full muscle strength", 
      "plasma exchange therapy", 
      "treatment of patients", 
      "randomized clinical trials", 
      "long-term outcomes", 
      "onset of disease", 
      "cost-minimization analysis", 
      "expensive strategy", 
      "motor recovery", 
      "moderate disease", 
      "muscle strength", 
      "mild group", 
      "clinical trials", 
      "complete cost data", 
      "moderate group", 
      "therapeutic strategies", 
      "medical outcomes", 
      "greater efficacy", 
      "syndrome", 
      "four-session", 
      "patients", 
      "healthcare system", 
      "outcomes", 
      "medical justification", 
      "treatment", 
      "minimization analysis", 
      "disease", 
      "trials", 
      "cost data", 
      "group", 
      "cost analysis", 
      "arm", 
      "therapy", 
      "mortality", 
      "recovery rate", 
      "efficacy", 
      "recovery", 
      "onset", 
      "sessions", 
      "strategies", 
      "years", 
      "dominant strategy", 
      "period", 
      "analysis", 
      "data", 
      "differences", 
      "euro", 
      "time", 
      "rate", 
      "assistance", 
      "cost", 
      "low cost", 
      "system", 
      "strength", 
      "exchange", 
      "justification", 
      "viewpoint"
    ], 
    "name": "Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barr\u00e9 syndrome", 
    "pagination": "1094-1100", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030486404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s001340051323"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11030166"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s001340051323", 
      "https://app.dimensions.ai/details/publication/pub.1030486404"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_327.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s001340051323"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s001340051323'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s001340051323'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s001340051323'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s001340051323'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      98 URIs      88 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s001340051323 schema:about N153fe1b23a724f6292374bc511704a98
2 N278f9777fd3b4f1eae5157e115cb63de
3 N4c2803efb2014525bad9ae32a8c1a62e
4 N777321d8a27f475db5cb685f33d7a1da
5 Nab85adb97a5347289bc2eeb3d06d5f2f
6 Ne397ae73abea49438892cadd6d5677f6
7 Ne3b2895c75d042c0ab5c557fef794f3e
8 Nf32cb92125344cf3a5636fd7898928c1
9 Nf89b274fa1c9420da806ba54972af0c1
10 Nf8a29b5334de4bb981a3caab4717a662
11 Nf974227dfe6749de993550d110468224
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author Nbcbf17a4f4f141eb937ca814c9171378
15 schema:citation sg:pub.10.1007/978-1-4899-3115-3
16 sg:pub.10.1007/s001340050595
17 schema:datePublished 2000-08
18 schema:datePublishedReg 2000-08-01
19 schema:description Objective: To undertake a cost analysis of therapeutic strategies with plasma exchange (PE) for the treatment of patients with Guillain-Barré syndrome. Design: A randomized clinical trial including 556 patients with Guillain-Barré syndrome. We demonstrated that in the group with mild disease (walking possible) two PEs were more effective than none in shortening the time to beginning motor recovery. In the groups with moderate disease (walking impossible) and or severe disease (mechanically ventilated patients) four sessions were more effective than two and no more effective than six in shortening the time to recovery of walking with assistance and for the recovery rate of full muscle strength within 1 year. Data on outcomes and costs was collected. Complete cost data were available on 546 from the 556 patients of the trial. Costs were estimated from the viewpoint of the healthcare system and computed over a 1-year period. Because the analysis of medical outcomes did not show any difference regarding mortality but only on intermediate short-term and long-term outcomes, we carried out a cost minimization analysis. Results: In two groups a dominant strategy appeared, with greater efficacy and lower costs in the two-PE arm for the mild group: 21,353 euros vs. 38,753 euros and in the four-PE arm in the moderate group: 59,480 euros vs. 80,737 euros. In the severe group four PEs were as efficient and somewhat less expensive than six: 57,621 vs. 61,056 euros. Conclusion: The treatment of Guillain-Barré syndrome by PE at the onset of disease appears to have medical justification. The least expensive strategies are either more or equally efficient as more expensive strategies.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N2c00d4699cb644a58feee0ca35d30b12
23 N5ba2eb3fab7b45fcae6d99f0d2a1eb43
24 sg:journal.1313639
25 schema:keywords Guillain-Barré syndrome
26 analysis
27 arm
28 assistance
29 clinical trials
30 complete cost data
31 cost
32 cost analysis
33 cost data
34 cost-minimization analysis
35 data
36 differences
37 disease
38 dominant strategy
39 efficacy
40 euro
41 exchange
42 expensive strategy
43 four-session
44 full muscle strength
45 greater efficacy
46 group
47 healthcare system
48 justification
49 long-term outcomes
50 low cost
51 medical justification
52 medical outcomes
53 mild group
54 minimization analysis
55 moderate disease
56 moderate group
57 mortality
58 motor recovery
59 muscle strength
60 onset
61 onset of disease
62 outcomes
63 patients
64 period
65 plasma exchange
66 plasma exchange therapy
67 randomized clinical trials
68 rate
69 recovery
70 recovery rate
71 sessions
72 strategies
73 strength
74 syndrome
75 system
76 therapeutic strategies
77 therapy
78 time
79 treatment
80 treatment of patients
81 trials
82 viewpoint
83 years
84 schema:name Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome
85 schema:pagination 1094-1100
86 schema:productId N4f1186deaf494e5ab23fc451ce811ee9
87 N962ea31af5014a57a5950ec6f53d60f3
88 Nb4c704bc11994386a0f6ab37139ec174
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030486404
90 https://doi.org/10.1007/s001340051323
91 schema:sdDatePublished 2022-10-01T06:31
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher Nf01f55d7880c4326865050c67f670f9d
94 schema:url https://doi.org/10.1007/s001340051323
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N153fe1b23a724f6292374bc511704a98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Plasma Exchange
100 rdf:type schema:DefinedTerm
101 N278f9777fd3b4f1eae5157e115cb63de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Sensitivity and Specificity
103 rdf:type schema:DefinedTerm
104 N2c00d4699cb644a58feee0ca35d30b12 schema:volumeNumber 26
105 rdf:type schema:PublicationVolume
106 N4c2803efb2014525bad9ae32a8c1a62e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Adult
108 rdf:type schema:DefinedTerm
109 N4f1186deaf494e5ab23fc451ce811ee9 schema:name doi
110 schema:value 10.1007/s001340051323
111 rdf:type schema:PropertyValue
112 N4f8ee5cb79fd42a7b5902f7e1eb0d43e rdf:first sg:person.01006317031.61
113 rdf:rest N6cfa04f18d954a67b4d37a92509281ed
114 N5ba2eb3fab7b45fcae6d99f0d2a1eb43 schema:issueNumber 8
115 rdf:type schema:PublicationIssue
116 N5eff9fbf84e34ad8aab43b1630921f51 rdf:first sg:person.015267023654.17
117 rdf:rest N4f8ee5cb79fd42a7b5902f7e1eb0d43e
118 N6cfa04f18d954a67b4d37a92509281ed rdf:first sg:person.012632056144.60
119 rdf:rest Nab6289025d7945d8a8aa63fdf4c08786
120 N777321d8a27f475db5cb685f33d7a1da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Cost-Benefit Analysis
122 rdf:type schema:DefinedTerm
123 N962ea31af5014a57a5950ec6f53d60f3 schema:name pubmed_id
124 schema:value 11030166
125 rdf:type schema:PropertyValue
126 Nab6289025d7945d8a8aa63fdf4c08786 rdf:first sg:person.01327533357.46
127 rdf:rest Ndc09458e5d334217bc5fe2b3452df8e4
128 Nab85adb97a5347289bc2eeb3d06d5f2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Severity of Illness Index
130 rdf:type schema:DefinedTerm
131 Nb4c704bc11994386a0f6ab37139ec174 schema:name dimensions_id
132 schema:value pub.1030486404
133 rdf:type schema:PropertyValue
134 Nbcbf17a4f4f141eb937ca814c9171378 rdf:first sg:person.0706141501.47
135 rdf:rest N5eff9fbf84e34ad8aab43b1630921f51
136 Nda54247b692949d18f1dbd7ad3316922 schema:familyName and the French Cooperative Group ¶on Plasma Exchange ¶in Guillain-Barré Syndrome
137 rdf:type schema:Person
138 Ndc09458e5d334217bc5fe2b3452df8e4 rdf:first Nda54247b692949d18f1dbd7ad3316922
139 rdf:rest rdf:nil
140 Ne397ae73abea49438892cadd6d5677f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Guillain-Barre Syndrome
142 rdf:type schema:DefinedTerm
143 Ne3b2895c75d042c0ab5c557fef794f3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Outcome Assessment, Health Care
145 rdf:type schema:DefinedTerm
146 Nf01f55d7880c4326865050c67f670f9d schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 Nf32cb92125344cf3a5636fd7898928c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Adolescent
150 rdf:type schema:DefinedTerm
151 Nf89b274fa1c9420da806ba54972af0c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 Nf8a29b5334de4bb981a3caab4717a662 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name France
156 rdf:type schema:DefinedTerm
157 Nf974227dfe6749de993550d110468224 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Statistics, Nonparametric
159 rdf:type schema:DefinedTerm
160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
161 schema:name Medical and Health Sciences
162 rdf:type schema:DefinedTerm
163 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
164 schema:name Clinical Sciences
165 rdf:type schema:DefinedTerm
166 sg:journal.1313639 schema:issn 0342-4642
167 1432-1238
168 schema:name Intensive Care Medicine
169 schema:publisher Springer Nature
170 rdf:type schema:Periodical
171 sg:person.01006317031.61 schema:affiliation grid-institutes:grid.411439.a
172 schema:familyName Bolgert
173 schema:givenName F.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006317031.61
175 rdf:type schema:Person
176 sg:person.012632056144.60 schema:affiliation grid-institutes:grid.414291.b
177 schema:familyName Raphaël
178 schema:givenName J.-C.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012632056144.60
180 rdf:type schema:Person
181 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.412116.1
182 schema:familyName Durand-Zaleski
183 schema:givenName I.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
185 rdf:type schema:Person
186 sg:person.015267023654.17 schema:affiliation grid-institutes:grid.414291.b
187 schema:familyName Jars-Guincestre
188 schema:givenName M.-C.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015267023654.17
190 rdf:type schema:Person
191 sg:person.0706141501.47 schema:affiliation grid-institutes:grid.413328.f
192 schema:familyName Espérou
193 schema:givenName H.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706141501.47
195 rdf:type schema:Person
196 sg:pub.10.1007/978-1-4899-3115-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109705857
197 https://doi.org/10.1007/978-1-4899-3115-3
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s001340050595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048034615
200 https://doi.org/10.1007/s001340050595
201 rdf:type schema:CreativeWork
202 grid-institutes:grid.411439.a schema:alternateName Medical Intensive Care Unit, La Salpétrière Hospital, Paris, France, FR
203 schema:name Medical Intensive Care Unit, La Salpétrière Hospital, Paris, France, FR
204 rdf:type schema:Organization
205 grid-institutes:grid.412116.1 schema:alternateName Department of Public Health, Henri Mondor Hospital AP-HP, Santé Publique, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre deTassigny, 94 010 Créteil, France e-mail: isabelle.durand-zaleski@hmn. ap-hop-paris.fr Tel.: + 33-1-49 81 36 74 Fax: + 33-1-49 81 36 97, FR
206 schema:name Department of Public Health, Henri Mondor Hospital AP-HP, Santé Publique, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre deTassigny, 94 010 Créteil, France e-mail: isabelle.durand-zaleski@hmn. ap-hop-paris.fr Tel.: + 33-1-49 81 36 74 Fax: + 33-1-49 81 36 97, FR
207 rdf:type schema:Organization
208 grid-institutes:grid.413328.f schema:alternateName Department of Hematology, Saint Louis Hospital, Paris, France, FR
209 schema:name Department of Hematology, Saint Louis Hospital, Paris, France, FR
210 rdf:type schema:Organization
211 grid-institutes:grid.414291.b schema:alternateName Medical Intensive Care Unit, Raymond Poincaré Hospital, Paris, France, FR
212 schema:name Medical Intensive Care Unit, Raymond Poincaré Hospital, Paris, France, FR
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...